The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Open accessAbstract
Nanoparticles have received enormous attention as a promising tool to enhance target-specific drug delivery and diagnosis. Various in vitro and in vivo techniques are used to characterize a new system and predict its clinical efficacy. These techniques enable efficient comparison across nanoparticles and facilitate a product optimization process. On the other hand, we recognize their limitations as a prediction tool, due to inadequate applications and overly simplified test conditions. We provide a critical review of in vitro and in vivo techniques currently used for evaluation of nanoparticles and introduce emerging techniques and models that may be used complementarily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
Laurell, C.-B. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90246-6 · Cited by 4,401
Regulated portals of entry into the cell
Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,805
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Kalyanasundaram, K., & Thomas, J. K. (1977) · Journal of the American Chemical Society · doi:10.1021/ja00449a004 · Cited by 3,464
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Research works printed but not linked: 33
- Saveyn H., 2010, J. Colloid Interface Sci., 352, 593, 10.1016/j.jcis.2010.09.006 · doi:10.1016/j.jcis.2010.09.006
- Finder C., 2004, Part. Part. Syst. Charact., 21, 372, 10.1002/ppsc.200400948 · doi:10.1002/ppsc.200400948
- Bowen P., 2002, J. Dispersion Sci. Technol., 23, 631, 10.1081/DIS-120015368 · doi:10.1081/dis-120015368
- Accardo A., 2004, J. Am. Chem. Soc., 126, 3097, 10.1021/ja039195b · doi:10.1021/ja039195b
- Needham D., 2000, Cancer Res., 60, 1197
- Pişkin E., 2004, Int. J. Pharm., 277, 105, 10.1016/j.ijpharm.2003.06.003 · doi:10.1016/j.ijpharm.2003.06.003
- Isaacs S. R., 2005, Chem. Mater., 18, 107, 10.1021/cm0518980 · doi:10.1021/cm0518980
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Zhang W., 2008, J. Microencapsulation, 25, 203, 10.1080/02652040701852181 · doi:10.1080/02652040701852181
- Boackle R., 1983, Mol. Immunol., 20, 1157, 10.1016/0161-5890(83)90139-6 · doi:10.1016/0161-5890(83)90139-6
- Suzuki Y., 2003, Carbohydr. Polym., 54, 465, 10.1016/j.carbpol.2003.07.002 · doi:10.1016/j.carbpol.2003.07.002
- Ekkapongpisit M., 2012, Int. J. Nanomed., 7, 4147
- Anirudhan T. S., 2011, New J. Chem., 35, 2869, 10.1039/c1nj20672a · doi:10.1039/c1nj20672a
- Han S. E., 2009, J. Drug Targeting, 17, 123, 10.1080/10611860802472461 · doi:10.1080/10611860802472461
- Lei T. J., 2011, Nanomedicine, 7, 324, 10.1016/j.nano.2010.11.004 · doi:10.1016/j.nano.2010.11.004
- Mitra M., 2012, Mol. Vision, 18, 1361
- Huang S. K., 1992, Cancer Res., 52, 6774
- Vaage J., 1994, Cancer, 73, 1478, 10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1 · doi:10.1002/1097-0142(19940301)73:5<1478::aid-cncr2820730526>3.0.co;2-1
- Vaage J., 1993, Cancer, 72, 3671, 10.1002/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U · doi:10.1002/1097-0142(19931215)72:12<3671::aid-cncr2820721219>3.0.co;2-u
- Van Oosterom A. T., 1986, Eur. J. Cancer Clin. Oncol., 22, 601, 10.1016/0277-5379(86)90050-7 · doi:10.1016/0277-5379(86)90050-7
- Lawton P. A., 1993, Clin. Oncol. (R. Coll. Radiol.), 5, 80, 10.1016/S0936-6555(05)80851-9 · doi:10.1016/s0936-6555(05)80851-9
- Cowan J. D., 1985, Invest. New Drugs, 3, 149, 10.1007/BF00174162 · doi:10.1007/bf00174162
- Pfeiffer P., 1992, Acta Oncol., 31, 219, 10.3109/02841869209088906 · doi:10.3109/02841869209088906
- Li C., 1998, Cancer Res., 58, 2404
- McDonald D. M., 2002, Cancer Res., 62, 5381
- Kuo T. H., 1993, Anticancer Res., 13, 627
- Hoffman R. M., 2005, Methods Mol. Med., 111, 297
- Chishima T., 1997, Cancer Res., 57, 2042
- El Hilali N., 2002, Lab. Invest., 82, 1563, 10.1097/01.LAB.0000036877.36379.1F · doi:10.1097/01.lab.0000036877.36379.1f
- Oh P., 2009, FASEB J., 23, 438.11
- Frost G. I., 2005, Microvasc. Res., 69, 1, 10.1016/j.mvr.2004.10.001 · doi:10.1016/j.mvr.2004.10.001
- Dibirdik I., 2010, J. Nanomed. Nanotechnol., 1, 001, 10.4172/2157-7439.1000101 · doi:10.4172/2157-7439.1000101
- Uckun F. M., 2004, Arzneim. Forsch., 54, 715
Cited by
Engineered nanoparticles interacting with cells: size matters
Shang, L., Nienhaus, K., & Nienhaus, G. U. (2014) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-12-5 · Cited by 1,316
A review on the classification, characterisation, synthesis of nanoparticles and their application
Anu Mary Ealia, S., & Saravanakumar, M. P. (2017) · IOP Conference Series: Materials Science and Engineering · doi:10.1088/1757-899x/263/3/032019 · Cited by 1,050
Khan, Y., Sadia, H., Ali Shah, S. Z., Khan, M. N., Shah, A. A., Ullah, N., Ullah, M. F., Bibi, H., Bafakeeh, O. T., Khedher, N. B., et al. (2022) · Catalysts · doi:10.3390/catal12111386 · Cited by 664
Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040883 · Cited by 531
Nanoparticle Characterization: What to Measure?
Modena, M. M., Rühle, B., Burg, T. P., & Wuttke, S. (2019) · Advanced Materials · doi:10.1002/adma.201901556 · Cited by 498
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Mukherjee, A., Waters, A. K., Kalyan, P., Achrol, A. S., Kesari, S., & Yenugonda, V. M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s198353 · Cited by 493
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Control of polymeric nanoparticle size to improve therapeutic delivery
Hickey, J. W., Santos, J. L., Williford, J.-M., & Mao, H.-Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.006 · Cited by 379
An Overview of the Algae-Mediated Biosynthesis of Nanoparticles and Their Biomedical Applications
Chaudhary, R., Nawaz, K., Khan, A. K., Hano, C., Abbasi, B. H., & Anjum, S. (2020) · Biomolecules · doi:10.3390/biom10111498 · Cited by 347
In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery
Jain, A. K., & Thareja, S. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1561457 · Cited by 319
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Release Kinetics Study of Poorly Water-Soluble Drugs from Nanoparticles: Are We Doing It Right?
Abouelmagd, S. A., Sun, B., Chang, A. C., Ku, Y. J., & Yeo, Y. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500817h · Cited by 259
Self-citationLiposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip
Kwak, B., Ozcelikkale, A., Shin, C. S., Park, K., & Han, B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.027 · Cited by 165
Abd Ellah, N. H., & Abouelmagd, S. A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213238 · Cited by 164
Self-citationSubhan, A., Mourad, A.-H. I., & Al-Douri, Y. (2022) · Nanomaterials · doi:10.3390/nano12132144 · Cited by 95
“Owing to their various functions, applications, and unique physiochemical properties, nanoparticles (NPs) have attained significant technological attention in the past [1].”
Background
Metadata
- Authors
- Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-03-21
- Volume
- 10
- Issue
- 6
- Pages
- 2093-2110
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1990424094
- Cited by
- 382
- References
- 181
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.